Antigen Discovery Inc.'s (ADi, formerly ImmPORT Therapeutics Inc. ) technology platform alleviates the major bottleneck that currently limits the transformation of genomic information into next generation medical advancements.

ADi’s high throughput technology surveys mammalian immune responses in a fast and comprehensive manner. The methods rapidly identify novel biomarkers, vaccine targets, and therapeutic protein candidates from infectious organisms, auto-immune disease states, and cancers.